Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chong-Jen Yu

Showing results (371-380 of 478) with videos related to

Pageof 48
Sort By:
The Lancet. Oncology|June 9, 2015
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, et al.
American Journal of Respiratory and Critical Care Medicine|November 19, 2016
SP110b Controls Host Immunity and Susceptibility to TuberculosisJia-Shiun Leu, Mei-Ling Chen, So-Yi Chang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysisLi-Yang Chen, Miguel A Molina-Vila, Sheng-Yuan Ruan, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 14, 2017
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBin-Chi Liao, Ya-Ying Bai, Jih-Hsiang Lee, et al.
JTO Clinical and Research Reports|September 30, 2021
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in <i>EGFR</i> T790M-Positive NSCLCBin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, et al.
Respiratory Medicine|September 8, 2012
Idiopathic pulmonary fibrosis in Taiwan - a population-based studyChih-Cheng Lai, Cheng-Yi Wang, Hsin-Ming Lu, et al.
Nature Communications|July 31, 2019
Mitofusins regulate lipid metabolism to mediate the development of lung fibrosisKuei-Pin Chung, Chia-Lang Hsu, Li-Chao Fan, et al.
American Journal of Respiratory and Critical Care Medicine|December 3, 2003
Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysemaPo-Nien Tsao, Yi-Ning Su, Hung Li, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|January 14, 2024
The impact of nontuberculous mycobacterial lung disease in critically ill patients: Significance for survival and ventilator useYing-Chun Chien, Chin-Hao Chang, Chun-Kai Huang, et al.
Antimicrobial Agents and Chemotherapy|December 28, 2020
Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort StudyShu-Yung Lin, Jia-Yih Feng, Chih-Yuan Lee, et al.
Pageof 48

Showing results (371-380 of 478) with videos related to

Sort By:
Pageof 48
The Lancet. Oncology|June 9, 2015
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, et al.
American Journal of Respiratory and Critical Care Medicine|November 19, 2016
SP110b Controls Host Immunity and Susceptibility to TuberculosisJia-Shiun Leu, Mei-Ling Chen, So-Yi Chang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysisLi-Yang Chen, Miguel A Molina-Vila, Sheng-Yuan Ruan, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 14, 2017
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBin-Chi Liao, Ya-Ying Bai, Jih-Hsiang Lee, et al.
JTO Clinical and Research Reports|September 30, 2021
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in <i>EGFR</i> T790M-Positive NSCLCBin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, et al.
Respiratory Medicine|September 8, 2012
Idiopathic pulmonary fibrosis in Taiwan - a population-based studyChih-Cheng Lai, Cheng-Yi Wang, Hsin-Ming Lu, et al.
Nature Communications|July 31, 2019
Mitofusins regulate lipid metabolism to mediate the development of lung fibrosisKuei-Pin Chung, Chia-Lang Hsu, Li-Chao Fan, et al.
American Journal of Respiratory and Critical Care Medicine|December 3, 2003
Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysemaPo-Nien Tsao, Yi-Ning Su, Hung Li, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|January 14, 2024
The impact of nontuberculous mycobacterial lung disease in critically ill patients: Significance for survival and ventilator useYing-Chun Chien, Chin-Hao Chang, Chun-Kai Huang, et al.
Antimicrobial Agents and Chemotherapy|December 28, 2020
Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort StudyShu-Yung Lin, Jia-Yih Feng, Chih-Yuan Lee, et al.
Pageof 48